surmount trials tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial ESC 2025: post-hoc SURMOUNT-5 data

During transitions between medications, blood sugar levels can become unpredictable

BAC declines at approximately 0.015% per hour after peak absorption, meaning a BAC of 0.08% requires approximately 5.3 hours to reach 0.00% through metabolism alone

, , .

Gastrointestinal symptoms: alteration in bowel motility, such as mild diarrhea or constipation, and loss of bladder or bowel control

Some individuals may experience a modest reduction in weight, while others may not see significant changes

As of early 2025, the FDA had received more than 455 adverse event reports involving compounded semaglutide and more than 320 involving compounded tirzepatide figures that the agency now cites as active justification for enforcement